Blinding Integrity and Psychedelic Drug Trials

JAMA Psychiatry · Published 2026-08-05 · DOI 10.1001/jamapsychiatry.2026.2293

Authors (2)

Michael Elliott, Olga Chernoloz

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Elliott, M., Chernoloz, O. (2026). Blinding Integrity and Psychedelic Drug Trials. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2026.2293

Related articles

• Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions · JAMA Psychiatry · 2026 · Cites or is cited by this article · Same journal
• GH001 vs Placebo in Patients With Treatment-Resistant Depression · JAMA Psychiatry · 2026 · Cites or is cited by this article · Same journal
• Optimizing Study Design for Clinically Useful Peripheral Molecular Biomarker Discovery in Psychiatry · JAMA Psychiatry · 2026 · Same journal
• Error in Table · JAMA Psychiatry · 2026 · Same journal
• Medication and Procedural Abortion and Risk of Psychotropic Medication Use · JAMA Psychiatry · 2026 · Same journal
• Assessing Drug Efficacy After Multiple Negative Trials—Gepirone’s Journey Through the FDA · JAMA Psychiatry · 2026 · Same journal
• Electroencephalography Microstates—A Biomarker for Psychosis? · JAMA Psychiatry · 2026 · Same journal
• Deconstructing Social Functioning in Psychosis Risk—From Prediction to Recovery · JAMA Psychiatry · 2026 · Same journal
• Confounding and Circularity in Actigraphy Prediction · JAMA Psychiatry · 2026 · Same journal
• Psychedelics Trials and Outcomes—A Closer Look—Reply · JAMA Psychiatry · 2026 · Same journal